BrightSpring Health Services Reports 44% EBITDA Growth as Specialty Pharmacy Drives Q2 Beat
The $13 billion healthcare services company posted second-quarter results ahead of expectations, fueled by robust performance in specialty pharmaceuticals and home health acquisitions.
Strong Quarter Across Segments
BrightSpring Health Services delivered second-quarter results that exceeded internal expectations, with total revenue reaching $3.9 billion, representing 23% year-over-year growth, and adjusted EBITDA of $206 million, up 44% from the prior year (earnings call, 2026-07-31). The company's adjusted EBITDA margin improved 80 basis points to 5.3%.
CEO Jon Rousseau attributed the performance to "the scale and complementary diversification of our platform across our target Home and Community end markets," along with operational execution and technology investments (earnings call, 2026-07-31).
Pharmacy Solutions Lead Growth
The Pharmacy Solutions segment generated $3.4 billion in revenue, up 22% year-over-year, with adjusted EBITDA of $180 million growing 44% versus the prior year. Within this segment, the Specialty and Infusion business delivered particularly strong results with 30% revenue growth and 31% script growth (earnings call, 2026-07-31).
The specialty business continues to be driven by branded oncology limited distribution drugs (LDDs), with the company adding two ultra-narrow network LDDs during the quarter to bring its total portfolio to 155. Year-to-date through Q2, BrightSpring launched 12 LDDs, including four as exclusive partners (earnings call, 2026-07-31).
The Home and Community Pharmacy business maintained high service levels despite volume impacts from exiting certain skilled nursing customers. CFO Jennifer Phipps noted these exits "in some cases has helped improve profitable growth year-to-date" (earnings call, 2026-07-31).
Provider Services Deliver Solid Performance
Provider Services revenue reached $466 million, up 30% year-over-year, with adjusted EBITDA of $75 million increasing 33%. The Home Health Care business showed volume growth above industry levels, supported by de novo investments and the integration of acquired Amedisys and LHC branches (earnings call, 2026-07-31).
Rousseau said the company now expects "an EBITDA contribution of approximately $35 million in 2026 from these acquired branches," with nearly 95% of branches maintaining four-star ratings or better (earnings call, 2026-07-31).
Balance Sheet Strengthens
BrightSpring generated $144 million in operating cash flow during the quarter, excluding a one-time $100 million tax payment related to the Community Living divestiture completed March 30, 2026. Leverage declined to 2.15x as of June 30, with the company now expecting approximately $600 million in operating cash flow for the full year and leverage below 2x before acquisitions (earnings call, 2026-07-31).
Both S&P and Moody's upgraded the company's credit ratings during the quarter, enabling a refinancing at a 50 basis point lower spread.
Industry Tailwinds
Rousseau highlighted that CMS released preliminary calendar year 2027 rates for home health services earlier in July, which include "a positive annual payment update, the first such upward adjustment in several years" (earnings call, 2026-07-31).
MarginX data shows recent insider activity included tax withholding transactions by CEO Jon Rousseau (56,319 shares) and CFO Scott Greenwell (2,487 shares), along with a stock award to director Nigam Shah (4,013 shares).
This article was generated by MarginX from the earnings call on 2026-07-31. It is not investment advice.